Owen Hughes Buys 62,000 Shares of CCCC
Insider Owen Hughes purchased 62,000 shares of CCCC on June 24, 2026.
Key Points
- Owen Hughes purchased 62,000 shares of CCCC on June 24, 2026, with the stock trading at $4.40.
- Morgan Stanley increased its holdings in CCCC by 90,738 shares, reaching 9,072,400 shares worth about $23.86 million.
- Analysts from Evercore ISI Group and others maintain a 'buy' rating on CCCC, with price targets ranging from $7 to $30.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Owen Hughes, an insider, recently bought 62,000 shares of CCCC on June 24, 2026. The transaction was not part of a pre-planned trading program. Shares of CCCC traded near $4.40 on Saturday.
Other Institutional Activity in CCCC
Morgan Stanley grew its holdings by 90,738 shares, ending with 9,072,400 shares valued at approximately $23.86 million. RA Capital Management, L.P. held steady with 8,000,000 shares worth about $21.04 million. Bain Capital Life Sciences Investors, LLC also maintained its position, holding 7,171,910 shares valued at $18.86 million. Lynx1 Capital Management LP reduced its stake by 99,231 shares, bringing its total to 6,998,902 shares, valued at $18.41 million. Meanwhile, Vanguard Capital Management LLC opened a new position with 3,861,852 shares valued at around $10.16 million.
Insider Buying and Selling at C4 Therapeutics, Inc.
Several insiders joined Owen Hughes in purchasing 62,000 shares each on June 24, 2026, including Steven Hoerter, Laura Bessen, Stephen Fawell, and Donna Roy Grogan. Kenneth Carl Anderson also bought 1,070 shares at an average price of $2.11 on June 1, 2026. None of these transactions were executed under a pre-planned trading program.
Analysts Set New Price Targets
On June 1, 2026, Evercore ISI Group maintained its 'buy' rating on CCCC with a price target of $12. Barclays, on February 27, 2026, kept its 'buy' rating with a target of $7. Brookline Capital also maintained a 'buy' rating with a $30 target on February 23, 2026. The consensus among analysts is a 'buy' recommendation, with a target mean price reflecting optimism about the company's future.
Bottom Line
Owen Hughes's purchase of CCCC shares signals a personal investment interest in the company. Institutional investors like Morgan Stanley are also adjusting their positions, indicating varying levels of confidence. Analysts continue to support CCCC with strong 'buy' ratings and ambitious price targets, reflecting positive sentiment in the market. Investors keep a close eye on these moves to gauge potential future performance.
Get C4 Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CCCC, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.